These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 32362349)

  • 21. Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis.
    Miao B; Chalupadi B; Clark B; Descoteaux A; Huang D; Ilham S; Ly B; Spyropoulos AC; Coleman CI
    Clin Appl Thromb Hemost; 2019; 25():1076029619850897. PubMed ID: 31088302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism.
    Fahmy M; Sylvester KW; Migliore M; Eguale T; Fanikos J; Connors JM; Goldhaber SZ
    J Thromb Thrombolysis; 2021 Jul; 52(1):22-29. PubMed ID: 33835335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
    J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
    Jamil A; Jamil U; Singh K; Khan F; Chi G
    Crit Pathw Cardiol; 2021 Mar; 20(1):16-24. PubMed ID: 32657973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
    Snoga JL; Benitez RM; Kim S; Creager O; Lusk KA
    Am J Health Syst Pharm; 2021 Jun; 78(12):1057-1065. PubMed ID: 33580664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
    Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES
    J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.
    Guy H; Laskier V; Fisher M; Neuman WR; Bucior I; Deitelzweig S; Cohen AT
    Pharmacoeconomics; 2019 May; 37(5):701-714. PubMed ID: 30578462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
    Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Lu W; Spiro TE; Barnathan ES; Raskob GE
    J Am Coll Cardiol; 2020 Jun; 75(25):3140-3147. PubMed ID: 32586587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
    Raskob GE; Ageno W; Albers G; Elliott CG; Halperin J; Maynard G; Steg PG; Weitz JI; Albanese J; Yuan Z; Levitan B; Lu W; Suh EY; Spiro T; Lipardi C; Barnathan ES; Spyropoulos AC
    J Am Heart Assoc; 2022 Oct; 11(20):e026229. PubMed ID: 36205248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of betrixaban and its role in clinical practice.
    Lekura J; Kalus JS
    Am J Health Syst Pharm; 2018 Aug; 75(15):1095-1102. PubMed ID: 29941506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
    Lee K; Cham S; Lam S
    Cardiol Rev; 2018; 26(6):331-338. PubMed ID: 30067518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs.
    Knotts TL; Mousa SA
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):365-376. PubMed ID: 30809772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.
    Yee MK; Nafee T; Daaboul Y; Korjian S; AlKhalfan F; Kerneis M; Wiest C; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
    J Thromb Thrombolysis; 2018 Jan; 45(1):1-8. PubMed ID: 29188425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis.
    Dobesh PP; Trevarrow BJ
    Am J Med; 2019 Mar; 132(3):307-311. PubMed ID: 30201249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
    Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA;
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients.
    Berkman SA
    Postgrad Med; 2021 Aug; 133(sup1):51-63. PubMed ID: 33435758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.
    Fanikos J; Rao A; Seger AC; Piazza G; Catapane E; Chen X; Goldhaber SZ
    Am J Med; 2011 Dec; 124(12):1143-50. PubMed ID: 22114828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.
    Chi G; Gibson CM; Hernandez AF; Hull RD; Kazmi SHA; Younes A; Walia SS; Pitliya A; Singh A; Kahe F; Kalayci A; Nafee T; Kerneis M; AlKhalfan F; Cohen AT; Harrington RA; Goldhaber SZ
    Am J Med; 2018 Aug; 131(8):972.e1-972.e7. PubMed ID: 29660351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New paradigms in venous thromboprophylaxis of medically ill patients.
    Spyropoulos AC; Raskob GE
    Thromb Haemost; 2017 Aug; 117(9):1662-1670. PubMed ID: 28640324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.